$42.67
0.44% yesterday
Nasdaq, Jun 13, 10:15 pm CET
ISIN
US92346J1088
Symbol
VCEL

Vericel Corporation Stock price

$42.67
-0.97 2.22% 1M
-14.80 25.75% 6M
-12.24 22.29% YTD
-0.68 1.57% 1Y
+27.91 189.09% 5Y
+39.12 1,100.28% 10Y
-389.33 90.12% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.19 0.45%
ISIN
US92346J1088
Symbol
VCEL
Sector

Key metrics

Market capitalization $2.14b
Enterprise Value $2.03b
P/E (TTM) P/E ratio 849.60
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 8.49
P/S ratio (TTM) P/S ratio 8.97
P/B ratio (TTM) P/B ratio 7.22
Revenue growth (TTM) Revenue growth 14.80%
Revenue (TTM) Revenue $238.54m
EBIT (operating result TTM) EBIT $-2.81m
Free Cash Flow (TTM) Free Cash Flow $-6.61m
Cash position $112.90m
EPS (TTM) EPS $0.05
P/E forward 173.38
P/S forward 7.47
EV/Sales forward 7.08
Short interest 11.90%
Show more

Is Vericel Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Vericel Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Vericel Corporation forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Vericel Corporation forecast:

Buy
100%

Financial data from Vericel Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
239 239
15% 15%
100%
- Direct Costs 66 66
3% 3%
27%
173 173
20% 20%
73%
- Selling and Administrative Expenses 150 150
19% 19%
63%
- Research and Development Expense 26 26
15% 15%
11%
4 4
264% 264%
2%
- Depreciation and Amortization 6.81 6.81
40% 40%
3%
EBIT (Operating Income) EBIT -2.81 -2.81
25% 25%
-1%
Net Profit 2.98 2.98
562% 562%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Vericel Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vericel Corporation Stock News

Positive
Seeking Alpha
one day ago
Vericel's valuation has moderated after a 20% share price drop, prompting a shift from sell to neutral. MACI remains the company's primary growth engine, with strong sales momentum and successful surgeon training on new indications. The stock enjoys bullish analyst firm support and Vericel's balance sheet is in a strong position.
Neutral
GlobeNewsWire
4 days ago
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Truist Securities MedTech Conference at 9:20 a.m. ET on Tuesday, June 17 2025.
Neutral
Investors Business Daily
26 days ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
More Vericel Corporation News

Company Profile

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Head office United States
CEO Dominick Colangelo
Employees 357
Founded 1989
Website vcel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today